These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31253477)

  • 1. Spanish Pompe registry: Baseline characteristics of first 49 patients with adult onset of Pompe disease.
    Alonso-Pérez J; Segovia S; Domínguez-González C; Olivé M; Mendoza Grimón MD; Fernández-Torrón R; López de Munain A; Muñoz-Blanco JL; Ramos-Fransi A; Almendrote M; Illa I; Díaz-Manera J
    Med Clin (Barc); 2020 Feb; 154(3):80-85. PubMed ID: 31253477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.
    Laforêt P; Laloui K; Granger B; Hamroun D; Taouagh N; Hogrel JY; Orlikowski D; Bouhour F; Lacour A; Salort-Campana E; Penisson-Besnier I; Sacconi S; Zagnoli F; Chapon F; Eymard B; Desnuelle C; Pouget J;
    Rev Neurol (Paris); 2013; 169(8-9):595-602. PubMed ID: 24008051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pompe disease: design, methodology, and early findings from the Pompe Registry.
    Byrne BJ; Kishnani PS; Case LE; Merlini L; Müller-Felber W; Prasad S; van der Ploeg A
    Mol Genet Metab; 2011 May; 103(1):1-11. PubMed ID: 21439876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
    Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
    Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry.
    Roberts M; Kishnani PS; van der Ploeg AT; Müller-Felber W; Merlini L; Prasad S; Case LE
    Mol Genet Metab; 2011 Dec; 104(4):574-82. PubMed ID: 21930409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.
    Lefeuvre C; De Antonio M; Bouhour F; Tard C; Salort-Campana E; Lagrange E; Behin A; Sole G; Noury JB; Sacconi S; Magot A; Nadaj-Pakleza A; Lacour A; Beltran S; Spinazzi M; Cintas P; Renard D; Michaud M; Bedat-Millet AL; Prigent H; Taouagh N; Arrassi A; Hamroun D; Attarian S; Laforêt P;
    Neurology; 2023 Aug; 101(9):e966-e977. PubMed ID: 37419682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
    Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
    Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
    Müller-Felber W; Horvath R; Gempel K; Podskarbi T; Shin Y; Pongratz D; Walter MC; Baethmann M; Schlotter-Weigel B; Lochmüller H; Schoser B
    Neuromuscul Disord; 2007 Oct; 17(9-10):698-706. PubMed ID: 17643989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial Pompe Disease.
    Tecellioglu M; Kamisli O
    Med Arch; 2015 Oct; 69(5):342-4. PubMed ID: 26622091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
    Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness.
    Johnson K; Töpf A; Bertoli M; Phillips L; Claeys KG; Stojanovic VR; Perić S; Hahn A; Maddison P; Akay E; Bastian AE; Łusakowska A; Kostera-Pruszczyk A; Lek M; Xu L; MacArthur DG; Straub V
    Orphanet J Rare Dis; 2017 Nov; 12(1):173. PubMed ID: 29149851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genetic modifier of symptom onset in Pompe disease.
    Bergsma AJ; In 't Groen SLM; van den Dorpel JJA; van den Hout HJMP; van der Beek NAME; Schoser B; Toscano A; Musumeci O; Bembi B; Dardis A; Morrone A; Tummolo A; Pasquini E; van der Ploeg AT; Pijnappel WWMP
    EBioMedicine; 2019 May; 43():553-561. PubMed ID: 30922962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Adult-onset Pompe Disease with Cerebral Stroke and Left Ventricular Hypertrophy.
    Hossain MA; Miyajima T; Akiyama K; Eto Y
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3046-3052. PubMed ID: 30093193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus treatment recommendations for late-onset Pompe disease.
    Cupler EJ; Berger KI; Leshner RT; Wolfe GI; Han JJ; Barohn RJ; Kissel JT;
    Muscle Nerve; 2012 Mar; 45(3):319-33. PubMed ID: 22173792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
    Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
    J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infantile-onset Pompe disease: Diagnosis and management.
    Bay LB; Denzler I; Durand C; Eiroa H; Frabasil J; Fainboim A; Maxit C; Schenone A; Spécola N
    Arch Argent Pediatr; 2019 Aug; 117(4):271-278. PubMed ID: 31339275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Pompe disease in China: a report from the Pompe registry.
    Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
    Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.